NASDAQ:SURF - Surface Oncology Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
$7.41 -0.41 (-5.24 %)
(As of 12/18/2018 04:00 PM ET)
Previous Close$7.82
Today's Range$7.12 - $7.99
52-Week Range$6.55 - $18.18
Volume184,900 shs
Average Volume202,289 shs
Market Capitalization$228.37 million
P/E RatioN/A
Dividend YieldN/A
Surface Oncology, Inc., a clinical-stage immuno-oncology company, engages in the development of cancer therapies. The company's lead product candidate is the SRF231 that is in Phase I clinical trial targeting protein called cluster of differentiation (CD) 47. It is also developing SRF373 inhibiting CD73; SRF617 inhibiting CD39; and SRF388, an antibody targeting interleukin 27. The company has a collaboration agreement with Novartis Institutes for Biomedical Research, Inc. for the development of cancer therapies. Surface Oncology, Inc. was founded in 2014 and is headquartered in Cambridge, Massachusetts.

Receive SURF News and Ratings via Email

Sign-up to receive the latest news and ratings for SURF and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange NASDAQ
Industry Biological products, except diagnostic
Current SymbolNASDAQ:SURF
Previous Symbol


Debt-to-Equity RatioN/A
Current Ratio6.44
Quick Ratio6.44


Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual Sales$6.63 million
Price / Sales30.94
Cash FlowN/A
Price / Cash FlowN/A
Book ValueN/A
Price / BookN/A


EPS (Most Recent Fiscal Year)N/A
Net IncomeN/A
Net MarginsN/A
Return on Equity-5.33%
Return on Assets-1.28%


Outstanding Shares27,680,000
Market Cap$228.37 million
OptionableNot Optionable

Surface Oncology (NASDAQ:SURF) Frequently Asked Questions

What is Surface Oncology's stock symbol?

Surface Oncology trades on the NASDAQ under the ticker symbol "SURF."

How were Surface Oncology's earnings last quarter?

Surface Oncology Inc (NASDAQ:SURF) posted its quarterly earnings results on Tuesday, November, 13th. The company reported ($0.62) EPS for the quarter, topping analysts' consensus estimates of ($0.68) by $0.06. The business had revenue of $1.73 million for the quarter, compared to the consensus estimate of $2 million. View Surface Oncology's Earnings History.

What price target have analysts set for SURF?

4 equities research analysts have issued 12 month target prices for Surface Oncology's stock. Their forecasts range from $17.00 to $26.00. On average, they anticipate Surface Oncology's stock price to reach $22.00 in the next year. This suggests a possible upside of 196.9% from the stock's current price. View Analyst Price Targets for Surface Oncology.

What is the consensus analysts' recommendation for Surface Oncology?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Surface Oncology in the last year. There are currently 1 hold rating and 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Surface Oncology.

Has Surface Oncology been receiving favorable news coverage?

News headlines about SURF stock have trended somewhat positive recently, according to InfoTrie Sentiment. The research group ranks the sentiment of news coverage by monitoring more than six thousand blog and news sources. The firm ranks coverage of public companies on a scale of -5 to 5, with scores closest to five being the most favorable. Surface Oncology earned a coverage optimism score of 1.9 on InfoTrie's scale. They also gave news stories about the company a news buzz of 1.0 out of 10, meaning that recent news coverage is extremely unlikely to have an impact on the stock's share price in the near term.

Are investors shorting Surface Oncology?

Surface Oncology saw a decrease in short interest in November. As of November 30th, there was short interest totalling 438,778 shares, a decrease of 26.1% from the November 15th total of 594,105 shares. Based on an average daily volume of 248,803 shares, the days-to-cover ratio is presently 1.8 days. Currently, 4.5% of the company's stock are short sold. View Surface Oncology's Current Options Chain.

Who are some of Surface Oncology's key competitors?

Who are Surface Oncology's key executives?

Surface Oncology's management team includes the folowing people:
  • Mr. Daniel S. Lynch, Exec. Chairman (Age 60)
  • Mr. J. Jeffrey Goater, CEO, Pres, Sec. & Director (Age 43)
  • Dr. Vito J. Palombella, Chief Scientific Officer (Age 55)
  • Dr. Scott C. Chappel, Chief Technology Officer (Age 67)
  • Dr. Robert W. Ross, Chief Medical Officer (Age 44)

When did Surface Oncology IPO?

(SURF) raised $84 million in an initial public offering on Thursday, April 19th 2018. The company issued 6,000,000 shares at $13.00-$15.00 per share. Goldman Sachs, Cowen and Evercore ISI served as the underwriters for the IPO.

Who are Surface Oncology's major shareholders?

Surface Oncology's stock is owned by a variety of of institutional and retail investors. Top institutional investors include FMR LLC (8.21%), EcoR1 Capital LLC (4.94%), Citadel Advisors LLC (3.83%), BlackRock Inc. (2.18%), Victory Capital Management Inc. (1.95%) and Vanguard Group Inc. (1.59%). Company insiders that own Surface Oncology stock include David S Grayzel and Lilly Ventures Fund I Llc. View Institutional Ownership Trends for Surface Oncology.

Which major investors are selling Surface Oncology stock?

SURF stock was sold by a variety of institutional investors in the last quarter, including FMR LLC, Victory Capital Management Inc. and BlackRock Inc.. View Insider Buying and Selling for Surface Oncology.

Which major investors are buying Surface Oncology stock?

SURF stock was acquired by a variety of institutional investors in the last quarter, including EcoR1 Capital LLC, Citadel Advisors LLC, Vanguard Group Inc, Vanguard Group Inc., Man Group plc, Marshall Wace North America L.P. and Strs Ohio. Company insiders that have bought Surface Oncology stock in the last two years include David S Grayzel and Lilly Ventures Fund I Llc. View Insider Buying and Selling for Surface Oncology.

How do I buy shares of Surface Oncology?

Shares of SURF can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Surface Oncology's stock price today?

One share of SURF stock can currently be purchased for approximately $7.41.

How big of a company is Surface Oncology?

Surface Oncology has a market capitalization of $228.37 million and generates $6.63 million in revenue each year. Surface Oncology employs 56 workers across the globe.

What is Surface Oncology's official website?

The official website for Surface Oncology is

How can I contact Surface Oncology?

Surface Oncology's mailing address is 50 HAMPSHIRE STREET 8TH FLOOR, CAMBRIDGE MA, 02139. The company can be reached via phone at 617-714-4096 or via email at [email protected]

MarketBeat Community Rating for Surface Oncology (NASDAQ SURF)

Community Ranking:  2.4 out of 5 (star star)
Outperform Votes:  51 (Vote Outperform)
Underperform Votes:  54 (Vote Underperform)
Total Votes:  105
MarketBeat's community ratings are surveys of what our community members think about Surface Oncology and other stocks. Vote "Outperform" if you believe SURF will outperform the S&P 500 over the long term. Vote "Underperform" if you believe SURF will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 12/18/2018 by Staff

Featured Article: SEC Filing

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.

Yahoo Gemini Pixel